Klaria Pharma Holding AB

KLAR

SE0007280326

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 15:12:50 17/05/2024 BST			5-day change	1st Jan Change
0.439 ^SEK	+8.40%		+12.28%	-4.98%

02-29	Klaria Pharma Holding AB (publ.) Reports Earnings Results for the Full Year Ended December 31, 2023	CI
02-29	Klaria Pharma Holding AB (publ.) Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Klaria Pharma Holding AB (Publ.) Announces Anders Ardstål Declines Re-Election

February 22, 2022 at 02:46 pm

Klaria Pharma Holding AB (publ.) announced that the current board member Anders Ardstål has declined re-election.

Latest news about Klaria Pharma Holding AB

Klaria Pharma Holding AB (publ.) Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Klaria Pharma Holding AB (publ.) Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-29	CI
Klaria Pharma Engages Ernst & Young to Review, Seek Strategic Partnerships	02-26	MT
Klaria Pharma Holding AB (publ.) Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-24	CI
Klaria Pharma Chief Executive Leaves; Chair Named Acting CEO	25/10/23	MT
Klaria Pharma Holding AB (publ.) Announces CEO Changes	25/10/23	CI
Klaria Pharma Holding AB (publ.) Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	25/08/23	CI
Klaria Pharma Holding AB (publ.) Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Klaria Pharma Faces Regulatory Probe on Inside Information Disclosures Over Rights Issue	28/03/23	MT
Klaria Pharma Holding AB (publ.) Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	10/02/23	CI
Klaria Pharma Holding AB (publ.) Reports Earnings Results for the Full Year Ended December 31, 2022	10/02/23	CI
Klaria Pharma Files EU Marketing Authorization Application for Migraine Treatment; Shares Up 10%	29/11/22	MT
Klaria Pharma Holding AB (publ.) Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	17/11/22	CI
Klaria Pharma, Pharma Mar to Collaborate on Feasibility Study	07/10/22	MT
Klaria Pharma Holding AB (publ.) Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	26/08/22	CI
Klaria Pharma Holding AB (publ.) Reports Earnings Results for the First Quarter Ended March 31, 2022	12/05/22	CI
Klaria Pharma, FluiMed Partner to Develop Sirolimus Alginate Film to Avoid Organ Transplant Rejection	30/03/22	MT
Klaria Pharmaceuticals Enters into Agreement with FluiMed GmbH to Develop Sirolimus Alginate Film for prevention of Organ Transplant Rejection	30/03/22	CI
Klaria Pharma Holding AB (publ.) announced that it has received funding	16/03/22	CI
Klaria Pharma Holding AB (publ.) announced a financing transaction	10/03/22	CI
Klaria Pharma Holding AB (Publ.) Announces Anders Ardstål Declines Re-Election	22/02/22	CI
Klaria Pharma Holding AB (publ.) Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	10/02/22	CI
Klaria Pharma Holding AB (publ.) Reports Earnings Results for the Full Year Ended December 31, 2021	10/02/22	CI
Klaria Pharma AB Initiates Clinical Study with Naloxon Alginate Film	20/12/21	CI
Klaria Pharma Wins Regulatory Nod To Launch Opioid Overdose Treatment Trial In UK	02/12/21	MT

Chart Klaria Pharma Holding AB

Duration

Period

More charts

Klaria Pharma Holding AB (publ) is a Sweden-based holding company engaged in the biotechnology and medical research industry. Through its group subsidiaries, the Company is active in developing and commercializing therapeutic drugs and treatment methods in the fields of migraine and pain related to cancer based on a patented drug delivery platform in the form of an alginate-based polymer film, which facilitates rapid and reliable transmucosal absorption via a muco-adhesive film. The Company operates Klaria Pharma AB as a wholly owned subsidiary.

Sector

Biotechnology & Medical Research

Calendar

22/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Klaria Pharma Holding AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
KLARIA PHARMA HOLDING AB	-4.98%	4.37M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-1.05%	21.96B
BIONTECH SE	-14.15%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs